B. Riley lowered the firm's price target on OptimizeRx to $10 from $11 and keeps a Buy rating on the shares. The underlying drivers of the second consecutive guidance revision, the top-3 client disruption and MFN-related contract duration compression, are largely transitory, and there is a credible path to growth re-acceleration in 2027 supported by continued DAAP subscription momentum, the eventual ramp of the DSP/programmatic channel, and the expected recovery of the top-3 client relationship, the analyst tells investors in a research note.
